Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients
Marinus Pharmaceuticals announces Phase 3 RAISE trial results for IV ganaxolone in refractory status epilepticus.
Marinus Pharmaceuticals Wraps Phase 3 Trial Enrollment for Tuberous Sclerosis Complex Treatment, Targets New Drug Application in 2025 Following Phase 3 Seizure Treatment Trial
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in the global Phase 3
Unveiling 10 Analyst Insights On Marinus Pharma
10 analysts have expressed a variety of opinions on Marinus Pharma (NASDAQ:MRNS) over the past quarter, offering a…
How Is The Market Feeling About Marinus Pharma?
Marinus Pharma’s (NYSE:MRNS) short percent of float has fallen 3.64% since its last report. The company recently reported…
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Analysts Question Commercial Viability of Marinus’ IV Ganaxolone After Interim Analysis Miss
Marinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review.
The Latest Analyst Ratings For Marinus Pharma
Ratings for Marinus Pharma (NASDAQ:MRNS) were provided by 7 analysts in the past three months, showcasing a mix…
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday.
The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also fell, dropping, 1.14% to 5,065.04.
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Longeveron (NASDAQ:LGVN) stock moved upwards by 44.4% to $2.44 during Monday’s regular session. The market value of…